Lyell Wealth Management LP Buys 677 Shares of IDEXX Laboratories, Inc. $IDXX

Lyell Wealth Management LP raised its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 3.0% during the 2nd quarter, Holdings Channel reports. The fund owned 23,142 shares of the company’s stock after purchasing an additional 677 shares during the period. Lyell Wealth Management LP’s holdings in IDEXX Laboratories were worth $12,412,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also bought and sold shares of IDXX. MorganRosel Wealth Management LLC acquired a new stake in shares of IDEXX Laboratories in the 1st quarter worth $26,000. Opal Wealth Advisors LLC acquired a new stake in shares of IDEXX Laboratories in the 2nd quarter worth $29,000. Migdal Insurance & Financial Holdings Ltd. boosted its position in shares of IDEXX Laboratories by 55.6% in the 1st quarter. Migdal Insurance & Financial Holdings Ltd. now owns 84 shares of the company’s stock worth $35,000 after purchasing an additional 30 shares in the last quarter. Ameritas Advisory Services LLC acquired a new stake in shares of IDEXX Laboratories in the 2nd quarter worth $36,000. Finally, WPG Advisers LLC acquired a new stake in shares of IDEXX Laboratories in the 1st quarter worth $37,000. Institutional investors own 87.84% of the company’s stock.

Insiders Place Their Bets

In other news, EVP Sharon E. Underberg sold 5,450 shares of the business’s stock in a transaction that occurred on Friday, August 8th. The stock was sold at an average price of $651.60, for a total value of $3,551,220.00. Following the completion of the sale, the executive vice president directly owned 6,156 shares in the company, valued at $4,011,249.60. The trade was a 46.96% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Michael Lane sold 8,411 shares of the business’s stock in a transaction that occurred on Wednesday, August 6th. The shares were sold at an average price of $627.74, for a total value of $5,279,921.14. Following the completion of the sale, the executive vice president owned 7,132 shares of the company’s stock, valued at $4,477,041.68. This trade represents a 54.11% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 54,057 shares of company stock valued at $34,293,468. 0.98% of the stock is owned by insiders.

IDEXX Laboratories Stock Performance

NASDAQ IDXX opened at $635.40 on Monday. The stock has a 50-day simple moving average of $639.99 and a two-hundred day simple moving average of $551.18. The firm has a market capitalization of $50.83 billion, a P/E ratio of 52.91, a PEG ratio of 4.11 and a beta of 1.58. IDEXX Laboratories, Inc. has a fifty-two week low of $356.14 and a fifty-two week high of $688.12. The company has a debt-to-equity ratio of 0.31, a quick ratio of 0.79 and a current ratio of 1.11.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings results on Monday, August 4th. The company reported $3.63 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.28 by $0.35. IDEXX Laboratories had a net margin of 24.41% and a return on equity of 64.42%. The firm had revenue of $1.11 billion for the quarter, compared to the consensus estimate of $1.06 billion. During the same period in the prior year, the firm posted $2.44 earnings per share. The firm’s quarterly revenue was up 10.6% compared to the same quarter last year. IDEXX Laboratories has set its FY 2025 guidance at 12.400-12.760 EPS. On average, equities analysts forecast that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current year.

Analysts Set New Price Targets

IDXX has been the subject of a number of recent analyst reports. BTIG Research raised their price objective on IDEXX Laboratories from $545.00 to $785.00 and gave the stock a “buy” rating in a research report on Tuesday, August 5th. Wall Street Zen lowered IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a research note on Sunday, September 28th. Leerink Partners raised their target price on IDEXX Laboratories from $580.00 to $600.00 and gave the stock an “outperform” rating in a research note on Thursday, July 17th. Morgan Stanley raised their target price on IDEXX Laboratories from $722.00 to $765.00 and gave the stock an “overweight” rating in a research note on Friday, August 15th. Finally, Weiss Ratings restated a “buy (b-)” rating on shares of IDEXX Laboratories in a research note on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat, IDEXX Laboratories currently has an average rating of “Moderate Buy” and a consensus price target of $656.50.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.